Cargando…
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial
IMPORTANCE: The protein-based SARS-CoV-2 vaccines FINLAY-FR-2 (Soberana 02) and FINLAY-FR-1A (Soberana Plus) showed good safety and immunogenicity in phase 1 and 2 trials, but the clinical efficacy of the vaccine remains unknown. OBJECTIVE: To evaluate the efficacy and safety of a 2-dose regimen of...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157429/ https://www.ncbi.nlm.nih.gov/pubmed/37133864 http://dx.doi.org/10.1001/jamanetworkopen.2023.10302 |
_version_ | 1785036751206612992 |
---|---|
author | Mostafavi, Ehsan Eybpoosh, Sana Karamouzian, Mohammad Khalili, Malahat Haji-Maghsoudi, Saiedeh Salehi-Vaziri, Mostafa Khamesipour, Ali Jalali, Tahmineh Nakhaeizadeh, Mehran Sharifi, Hamid Mansoori, Yasaman Keramat, Fariba Ghodrati, Samad Javanian, Mostafa Doroud, Delaram Omrani, Mir Davood Asadi, Hassan Pouriayevali, Mohammad Hassan Ghasemian, Roya Farshidi, Hossein Pourahmad, Morteza Ghasemzadeh, Iman Mounesan, Leila Darvishian, Maryam Mirjalili, Mohamad Reza Toledo-Romani, Maria Eugenia Valenzuela-Silva, Carmen Verez-Bencomo, Vicente Gouya, Mohammad Mehdi Emadi-Koochak, Hamid Haghdoost, Ali Akbar Biglari, Alireza |
author_facet | Mostafavi, Ehsan Eybpoosh, Sana Karamouzian, Mohammad Khalili, Malahat Haji-Maghsoudi, Saiedeh Salehi-Vaziri, Mostafa Khamesipour, Ali Jalali, Tahmineh Nakhaeizadeh, Mehran Sharifi, Hamid Mansoori, Yasaman Keramat, Fariba Ghodrati, Samad Javanian, Mostafa Doroud, Delaram Omrani, Mir Davood Asadi, Hassan Pouriayevali, Mohammad Hassan Ghasemian, Roya Farshidi, Hossein Pourahmad, Morteza Ghasemzadeh, Iman Mounesan, Leila Darvishian, Maryam Mirjalili, Mohamad Reza Toledo-Romani, Maria Eugenia Valenzuela-Silva, Carmen Verez-Bencomo, Vicente Gouya, Mohammad Mehdi Emadi-Koochak, Hamid Haghdoost, Ali Akbar Biglari, Alireza |
author_sort | Mostafavi, Ehsan |
collection | PubMed |
description | IMPORTANCE: The protein-based SARS-CoV-2 vaccines FINLAY-FR-2 (Soberana 02) and FINLAY-FR-1A (Soberana Plus) showed good safety and immunogenicity in phase 1 and 2 trials, but the clinical efficacy of the vaccine remains unknown. OBJECTIVE: To evaluate the efficacy and safety of a 2-dose regimen of FINLAY-FR-2 (cohort 1) and a 3-dose regimen of FINLAY-FR-2 with FINLAY-FR-1A (cohort 2) in Iranian adults. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial was conducted at 6 cities in cohort 1 and 2 cities in cohort 2. Participants included individuals aged 18 to 80 years without uncontrolled comorbidities, coagulation disorders, pregnancy or breastfeeding, recent immunoglobulin or immunosuppressive therapy, and clinical presentation or laboratory-confirmed COVID-19 on enrollment. The study was conducted from April 26 to September 25, 2021. INTERVENTIONS: In cohort 1, 2 doses of FINLAY-FR-2 (n = 13 857) or placebo (n = 3462) were administered 28 days apart. In cohort 2, 2 doses of FINLAY-FR-2 plus 1 dose of FINLAY-FR-1A (n = 4340) or 3 placebo doses (n = 1081) were administered 28 days apart. Vaccinations were administered via intramuscular injection. MAIN OUTCOMES AND MEASURES: The primary outcome was polymerase chain reaction–confirmed symptomatic COVID-19 infection at least 14 days after vaccination completion. Other outcomes were adverse events and severe COVID-19. Intention-to-treat analysis was performed. RESULTS: In cohort 1 a total 17 319 individuals received 2 doses and in cohort 2 5521 received 3 doses of the vaccine or placebo. Cohort 1 comprised 60.1% men in the vaccine group and 59.1% men in the placebo group; cohort 2 included 59.8% men in the vaccine group and 59.9% in the placebo group. The mean (SD) age was 39.3 (11.9) years in cohort 1 and 39.7 (12.0) years in cohort 2, with no significant difference between the vaccine and placebo groups. The median follow-up time in cohort 1 was 100 (IQR, 96-106) days and, in cohort 2, 142 (137-148) days. In cohort 1, 461 (3.2%) cases of COVID-19 occurred in the vaccine group and 221 (6.1%) in the placebo group (vaccine efficacy: 49.7%; 95% CI, 40.8%-57.3%) vs 75 (1.6%) and 51 (4.3%) in cohort 2 (vaccine efficacy: 64.9%; 95% CI, 49.7%-59.5%). The incidence of serious adverse events was lower than 0.1%, with no vaccine-related deaths. CONCLUSIONS AND RELEVANCE: In this multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of FINLAY-FR-2 and FINLAY-FR-1A, 2 doses of FINLAY-FR-2 plus the third dose of FINLAY-FR-1A showed acceptable vaccine efficacy against symptomatic COVID-19 as well as COVID-19–related severe infections. Vaccination was generally safe and well tolerated. Therefore, Soberana may have utility as an option for mass vaccination of the population, especially in resource-limited settings, because of its storage condition and affordable price. TRIAL REGISTRATION: isrctn.org Identifier: IRCT20210303050558N1 |
format | Online Article Text |
id | pubmed-10157429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-101574292023-05-05 Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial Mostafavi, Ehsan Eybpoosh, Sana Karamouzian, Mohammad Khalili, Malahat Haji-Maghsoudi, Saiedeh Salehi-Vaziri, Mostafa Khamesipour, Ali Jalali, Tahmineh Nakhaeizadeh, Mehran Sharifi, Hamid Mansoori, Yasaman Keramat, Fariba Ghodrati, Samad Javanian, Mostafa Doroud, Delaram Omrani, Mir Davood Asadi, Hassan Pouriayevali, Mohammad Hassan Ghasemian, Roya Farshidi, Hossein Pourahmad, Morteza Ghasemzadeh, Iman Mounesan, Leila Darvishian, Maryam Mirjalili, Mohamad Reza Toledo-Romani, Maria Eugenia Valenzuela-Silva, Carmen Verez-Bencomo, Vicente Gouya, Mohammad Mehdi Emadi-Koochak, Hamid Haghdoost, Ali Akbar Biglari, Alireza JAMA Netw Open Original Investigation IMPORTANCE: The protein-based SARS-CoV-2 vaccines FINLAY-FR-2 (Soberana 02) and FINLAY-FR-1A (Soberana Plus) showed good safety and immunogenicity in phase 1 and 2 trials, but the clinical efficacy of the vaccine remains unknown. OBJECTIVE: To evaluate the efficacy and safety of a 2-dose regimen of FINLAY-FR-2 (cohort 1) and a 3-dose regimen of FINLAY-FR-2 with FINLAY-FR-1A (cohort 2) in Iranian adults. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial was conducted at 6 cities in cohort 1 and 2 cities in cohort 2. Participants included individuals aged 18 to 80 years without uncontrolled comorbidities, coagulation disorders, pregnancy or breastfeeding, recent immunoglobulin or immunosuppressive therapy, and clinical presentation or laboratory-confirmed COVID-19 on enrollment. The study was conducted from April 26 to September 25, 2021. INTERVENTIONS: In cohort 1, 2 doses of FINLAY-FR-2 (n = 13 857) or placebo (n = 3462) were administered 28 days apart. In cohort 2, 2 doses of FINLAY-FR-2 plus 1 dose of FINLAY-FR-1A (n = 4340) or 3 placebo doses (n = 1081) were administered 28 days apart. Vaccinations were administered via intramuscular injection. MAIN OUTCOMES AND MEASURES: The primary outcome was polymerase chain reaction–confirmed symptomatic COVID-19 infection at least 14 days after vaccination completion. Other outcomes were adverse events and severe COVID-19. Intention-to-treat analysis was performed. RESULTS: In cohort 1 a total 17 319 individuals received 2 doses and in cohort 2 5521 received 3 doses of the vaccine or placebo. Cohort 1 comprised 60.1% men in the vaccine group and 59.1% men in the placebo group; cohort 2 included 59.8% men in the vaccine group and 59.9% in the placebo group. The mean (SD) age was 39.3 (11.9) years in cohort 1 and 39.7 (12.0) years in cohort 2, with no significant difference between the vaccine and placebo groups. The median follow-up time in cohort 1 was 100 (IQR, 96-106) days and, in cohort 2, 142 (137-148) days. In cohort 1, 461 (3.2%) cases of COVID-19 occurred in the vaccine group and 221 (6.1%) in the placebo group (vaccine efficacy: 49.7%; 95% CI, 40.8%-57.3%) vs 75 (1.6%) and 51 (4.3%) in cohort 2 (vaccine efficacy: 64.9%; 95% CI, 49.7%-59.5%). The incidence of serious adverse events was lower than 0.1%, with no vaccine-related deaths. CONCLUSIONS AND RELEVANCE: In this multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of FINLAY-FR-2 and FINLAY-FR-1A, 2 doses of FINLAY-FR-2 plus the third dose of FINLAY-FR-1A showed acceptable vaccine efficacy against symptomatic COVID-19 as well as COVID-19–related severe infections. Vaccination was generally safe and well tolerated. Therefore, Soberana may have utility as an option for mass vaccination of the population, especially in resource-limited settings, because of its storage condition and affordable price. TRIAL REGISTRATION: isrctn.org Identifier: IRCT20210303050558N1 American Medical Association 2023-05-03 /pmc/articles/PMC10157429/ /pubmed/37133864 http://dx.doi.org/10.1001/jamanetworkopen.2023.10302 Text en Copyright 2023 Mostafavi E et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Mostafavi, Ehsan Eybpoosh, Sana Karamouzian, Mohammad Khalili, Malahat Haji-Maghsoudi, Saiedeh Salehi-Vaziri, Mostafa Khamesipour, Ali Jalali, Tahmineh Nakhaeizadeh, Mehran Sharifi, Hamid Mansoori, Yasaman Keramat, Fariba Ghodrati, Samad Javanian, Mostafa Doroud, Delaram Omrani, Mir Davood Asadi, Hassan Pouriayevali, Mohammad Hassan Ghasemian, Roya Farshidi, Hossein Pourahmad, Morteza Ghasemzadeh, Iman Mounesan, Leila Darvishian, Maryam Mirjalili, Mohamad Reza Toledo-Romani, Maria Eugenia Valenzuela-Silva, Carmen Verez-Bencomo, Vicente Gouya, Mohammad Mehdi Emadi-Koochak, Hamid Haghdoost, Ali Akbar Biglari, Alireza Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial |
title | Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial |
title_full | Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial |
title_fullStr | Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial |
title_full_unstemmed | Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial |
title_short | Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial |
title_sort | efficacy and safety of a protein-based sars-cov-2 vaccine: a randomized clinical trial |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157429/ https://www.ncbi.nlm.nih.gov/pubmed/37133864 http://dx.doi.org/10.1001/jamanetworkopen.2023.10302 |
work_keys_str_mv | AT mostafaviehsan efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT eybpooshsana efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT karamouzianmohammad efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT khalilimalahat efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT hajimaghsoudisaiedeh efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT salehivazirimostafa efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT khamesipourali efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT jalalitahmineh efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT nakhaeizadehmehran efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT sharifihamid efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT mansooriyasaman efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT keramatfariba efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT ghodratisamad efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT javanianmostafa efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT dorouddelaram efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT omranimirdavood efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT asadihassan efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT pouriayevalimohammadhassan efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT ghasemianroya efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT farshidihossein efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT pourahmadmorteza efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT ghasemzadehiman efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT mounesanleila efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT darvishianmaryam efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT mirjalilimohamadreza efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT toledoromanimariaeugenia efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT valenzuelasilvacarmen efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT verezbencomovicente efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT gouyamohammadmehdi efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT emadikoochakhamid efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT haghdoostaliakbar efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial AT biglarialireza efficacyandsafetyofaproteinbasedsarscov2vaccinearandomizedclinicaltrial |